Angiogenesis and reproduction
2001; Wiley; Volume: 108; Issue: 8 Linguagem: Inglês
10.1111/j.1471-0528.2001.00211.x
ISSN1471-0528
Autores Tópico(s)Blood Coagulation and Thrombosis Mechanisms
ResumoBJOG: An International Journal of Obstetrics & GynaecologyVolume 108, Issue 8 p. 777-783 Angiogenesis and reproduction S.K. Smith, S.K. Smith Department of Obstetrics and Gynaecology and Pathology, Addenbrooke's Hospital, Cambridge, UKSearch for more papers by this author S.K. Smith, S.K. Smith Department of Obstetrics and Gynaecology and Pathology, Addenbrooke's Hospital, Cambridge, UKSearch for more papers by this author First published: 22 December 2003 https://doi.org/10.1111/j.1471-0528.2001.00211.xCitations: 17Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Folkman J., Shing Y., Angiogenesis J., Biol Chem 1992: 267: 10931–10934. 2 Carmeliet P., Moons L., Dewerchin M., et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann New York Acad Sci 1997; 811: 191–206. 3 Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–439. 4 Risau W., Flamme I.. Vasculogenesis. Annu Rev Cell Dev Biol 1995; 11: 73–91. 5 Folkman J.. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31. 6 Flamme I., Risau W.. Mechanism of blood vessel formation. Ann Anatomy 1995; 177: 493–502. 7 Beck L., Jr, D'Amore P.A.. Vascular development: cellular and molecular regulation. FASEB J 1997; 11: 365–373. 8 Ortega N., L'Faqihi F.E., Plouet J.. Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix. Biol Cell 1998; 90: 381–390. 9 Breier G., Damert A., Plate K.H., Risau W.. Angiogenesis in embryos and ischemic diseases. Thromb Haemost 1997; 78: 678–683. 10 Ferrara N., Davis-Smyth T.. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4–25. 11 Pepper M.S., Vassalli J.D., Orci L., Montesano R.. Biphasic effect of transforming growth factor-beta1 on in vitro angiogenesis. Exp Cell Res 1993; 204: 356–363. 12 O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285. 13 O'Reilly M.S., Pirie-Shepherd S., Lane W.S., Folkman J.. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin [see comments]. Science 1999; 285: 1926–1928. 14 O'Reilly M.S., Holmgren L., Chen C., Folkman J.. Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat Med 1996; 2: 689–692. 15 Risau W.. Mechanisms of angiogenesis. Nature 1997; 386: 671–674. 16 Brooks P.C., Clark R.A.F., Cheresh D.A.. Requirement of vascular integrin alpha(v)beta3 for angiogenesis. Science 1994; 264: 569–571. 17 Meeson A.P., Argilla M., Ko K., Witte L., Lang R.A.. VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development 1999; 126: 1407–1415. 18 Carmeliet P., Lampugnani M.G., Moons L., et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98: 147–157. 19 Hanahan D.. Signalling vascular morphogenesis and maintenance. Science 1997; 277: 48–50. 20 Hirschi K.K., D'Amore P.A.. Pericytes in the microvasculature. Cardiovasc Res 1996; 32: 687–698. 21 Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171–1180. 22 Davis S., Aldrich T.H., Jones P.F., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161–1169. 23 Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55–60. 24 Salamonsen L.A.. Matrix metalloproteinases and endometrial remodelling. Cell Biol Int 1995; 18: 1139–1144. 25 Marbaix E., Kokorine I., Donnez J., Courtoy P.J., Eeckhout Y.. Collagenase and related matrix metalloproteinases: a prominent role in the initiation of menstruation?. Medecine/Sciences 1995; 11: 1261–1269. 26 Schatz F., Papp C., Toth-Pal E., Lockwood C.J.. Ovarian steroid-modulated stromelysin-1 expression in human endometrial stromal and decidual cells. J Clin Endocrinol Metab 1994; 78: 1467–1472. 27 Irwin J.C., Kirk D., Gwatkin R.B.L., Navre M., Cannon P., Giudice L.C.. Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase. Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle. J Clin Investig 1996; 97: 438–447. 28 Lockwood C.J., Schatz F.. A biological model for the regulation of peri-implantation hemostasis and menstruation. J Soc Gynecol Invest 1996; 3: 159–165. 29 Kokorine I., Marbaix E., Henriet P., et al. Focal cellular origin and regulation of interstitial collagenase (matrix metalloproteinase-1) are related to menstrual breakdown in the human endometrium. J Cell Science 1996; 109: 2151–2160. 30 Ludwig H., Metzger H., Frauli M.. Endometrium: tissue remodelling and regeneration. C. D'Arcangues, I.S. Fraser, J.R. Newton, V. Odlind, Contraception and Mechanisms of Endometrial Bleeding. Cambridge : Cambridge University Press, 1990: 441–466. 31 Ludwig H., Metzger H.. The human female reproductive tract: A scanning electron microscopic Atlas. New York : Springer-Verlag, 1976. 32 Rogers P.A.W., Au S.L., Affandi B.. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod 1993; 8: 1396–1404. 33 Goodger A.M., Rogers P.A.W.. Endometrial endothelial cell proliferation during the menstrual cycle. Hum Reprod 1994; 9: 399–405. 34 Rogers P.A.W., Abberton S., Susil B.. Endothelial cell migratory signal produced by human endometrium during the menstrual cycle. Hum Reprod 1992; 7: 1061–1066. 35 Rogers P.A., Lederman F., Taylor N.. Endometrial microvascular growth in normal and dysfunctional states. Hum Reprod Update 1998; 4: 503–508. 36 Rogers P.A.W., Lederman F., Kooy J., Taylor N.H., Healy D.L.. Endometrial vascular smooth muscle oestrogen and progesterone receptor distribution in women with and without menorrhagia. Hum Reprod 1996; 11: 2003–2008. 37 Smith S.K.. Angiogenesis, vascular endothelial growth factor and the endometrium. Hum Reprod Update 1998; 4: 509–519. 38 Kooy J., Taylor N.H., Healy D.L., Rogers P.A.W.. Endothelial cell proliferation in the endometrium of women with menorrhagia and in women following endometrial ablation. Hum Reprod 1996; 11: 1067–1072. 39 Abberton K.M., Taylor N.H., Healy D.L., Rogers P.A.W.. Vascular smooth muscle alpha-actin distribution around endometrial arterioles during the menstrual cycle: increased expression during the perimenopause and lack of correlation with menorrhagia. Hum Reprod 1996; 11: 204–211. 40 Gargett C.E., Lederman F.L., Lau T.M., Taylor N.H., Rogers P.A.. Lack of correlation between vascular endothelial growth factor production and endothelial cell proliferation in the human endometrium. Hum Reprod 1999; 14: 2080–2088. 41 Hickey M., Dwarte D., Fraser I.S.. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod 2000; 15: 1509–1514. 42 Oosterlynck D.J., Meuleman C., Sobis H., Vandeputte M., Koninckx P.R.. Angiogenic activity of peritoneal fluid from women with endometriosis. Fertil Steril 1993; 59: 778–782. 43 McLaren J., Prentice A., Charnock-Jones D.S., Smith S.K.. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996; 11: 220–223. 44 Wingfield M., Macpherson A., Healy D.L., Rogers P.A.. Cell proliferation is increased in the endometrium of women with endometriosis. Fertil Steril 1995; 64: 340–346. 45 Matsuzaki S., Canis M., Darcha C., Dechelotte P., Pouly J.L., Bruhat M.A.. Angiogenesis in endometriosis. Gynecol Obstet Invest 1998; 46: 111–115. 46 McLaren J., Prentice A., Charnock-Jones D.S., et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996; 98: 482–489. 47 Goede V., Schmidt T., Kimmina S., Kozian D., Augustin H.G.. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1989; 78: 1385–1394. 48 Charnock-Jones D.S., Smith S.K.. Vascular endothelial growth factor and corpus luteum angiogenesis. Angiogenesis 1998; 2: 119–121. 49 Ferrara N., Chen H., Davis-Smyth T., et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 336–340. 50 Asan E., Kaymaz F.F., Cakar A.N., Dagdeviren A., Beksac M.S.. Vasculogenesis in early human placental villi: An ultrastructural study. Ann Anatomy 1999; 181: 549–554. 51 Clauss M.. Functions of the VEGF receptor-1 (FLT-1) in the vasculature. Trends in Cardiovas Med 1998; 8: 241–245. 52 Shalaby F., Rossant J., Yamaguchi T.P., et al. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 1995; 376: 62–66. 53 Zhou Y., Fisher S.J., Janatpour M., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate: a strategy for successful endovascular invasion?. J Clin Invest 1997; 99: 2139–2151. 54 Clark D.E., Smith S.K., He Y., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540–1548. 55 He Y., Smith S.K., Day K.A., Clark D.E., Licence D.R., Charnock-Jones D.S.. Alternative splicing of vascular endothelial growth factor (VEGF)-R1(FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999; 13: 537–545. 56 Roberts J.M.. Endothelial dysfunction in preeclampsia. Sem Reprod Endocrinol 1998; 16: 5–15. 57 Johnston R.W.. Toxaemias of pregnancy. A Textbook of Midwifery. London : A&C Black, 1939: 237–259. 58 Baker P.N., Krasnow J., Roberts J.M., Yeo K.T.. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 1995; 86: 815–821. 59 Sharkey A.M., Cooper J.C., Balmforth J.R., et al. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies-complicated by pre-eclampsia. Europ J Clin Investig 1996; 26: 1182–1185. 60 Brockelsby J., Hayman R., Ahmed A., Warren A., Johnson I., Baker P.. VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia. Lab Invest 1999; 79: 1101–1111. 61 Torry D.S., Wang H.S., Wang T.H., Caudle M.R., Torry R.J.. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1999; 179: 1539–1544. 62 Boocock C.A., Charnock-Jones D.S., Sharkey A.M., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506–516. 63 Sowter H.M., Corps A.N., Evans A.L., Clark D.E., Charnock-Jones D.S., Smith S.K.. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997; 77: 607–614. 64 Mesiano S., Ferrara N., Jaffe R.B.. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153: 1249–1256. 65 Martoglio A.M., Tom B.D.M., Starkey M., Corps A.N., Charnock-Jones D.S., Smith S.K.. Changes in tumorigenesis- and angiogenesis-related gene expression in ovarian cancer detected by tailored high density cDNA arrays. Mol Med 2000; 6: 750–765. 66 Davies B.R., Finnigan D.S., Smith S.K., Ponder B.A.J.. Administration of gonadotrophins stimulates proliferation of normal mouse ovarian surface epithelium. Gynaecol Endocrinol 1999; 13: 75–81. 67 Schiffenbauer Y.S., Abramovitch R., Meir G., et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Nat Acad Sci USA 1997; 94: 13203–13208. 68 Guidi A.J., Abu-Jawdeh G., Berse B., et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995; 87: 1237–1245. 69 Tjalma W., Van Marck E., Weyler J., et al. Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer. Br J Cancer 1998; 78: 170–174. 70 Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994–1998. 71 Mukhopadhyay D., Tsiokas L., Sukhatme V.P.. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161–6165. 72 Riccioni T., Cirielli C., Wang X., Passaniti A., Capogrossi M.C.. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. Gene Ther 1998; 5: 747–754. 73 Salvesen H.B., Akslen L.A.. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999; 84: 538–543. 74 Fraser H.M., Lunn S.F., Kim H., et al. Changes in insulin-like growth factor-binding protein-3 messenger ribonucleic acid in endothelial cells of the human corpus luteum: A possible role in luteal development and rescue. J Clin Endocr Metab 2000; 85: 1672–1677. 75 Sutton C.J.G., Pooley A.S., Ewen S.P., Haines P.. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril 1997; 68: 1070–1074. 76 Smith S.K.. Angiogenesis and ovarian cancer. Contemp Rev Obstet Gynaecol 1997; 9: 53–59. 77 Kendall R.L., Thomas K.A.. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Nat Acad Sci USA 1993; 90: 10705–10709. 78 Brooks P.C., Montgomery A.M.P., Rosenfeld M., et al. Integrin alpha(v)beta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessel. Cell 1994; 79: 1157–1164. 79 Fujimoto J., Hori M., Ichigo S., Hirose R., Sakaguchi H., Tamaya T.. Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Lett 1997; 113: 187–194. 80 Soker S., Takashima S., Hua Quan M., Neufeld G., Klagsbrun M.. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endotyhelial growth factor. Cell 1998; 92: 735–745. 81 Migdal M., Huppertz B., Tessler S., et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998; 273: 22272–22278. 82 Giger R.J., Urquhart E.R., Gillespie S.K.H., Levengood D.V., Ginty D.D., Kolodkin A.L.. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 1999; 21: 1079–1092. 83 Yancopoulos G.D., Klagsbrun M., Folkman J.. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998; 93: 661–664. 84 Pepper M.S.. Manipulating angiogenesis: from basic science to the bedside. Arterio Thromb Vas Biol 1997; 17: 605–619. 85 Tilton R.G., Dixon R.A.F., Brock T.A.. Growth factor antagonists for the treatment of diabetic vascular complications. Expert Opinion on Investigational Drugs 1997; 6: 1671–1684. 86 Stehouwer C.D.A., Lambert J., Donker A.J.M., Van Hinsbergh V.W.M.. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovas Res 1997; 34: 55–68. 87 Koch A.E.. Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998; 41: 951–962. 88 Hahnfelt P., Panigraphy D., Folkman J., Hlatky L.. Tumor development under angiogenic signalling: a dynamic theory of tumor. Cancer Res 1999; 59: 4770–4775. Citing Literature Volume108, Issue8August 2001Pages 777-783 ReferencesRelatedInformation
Referência(s)